SKU: DPH45 | Published On: | Available Formats
Please Enter the information below
By Drug Type
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of neuroendocrine cancer.
The operation is the primary treatment for Neuroendocrine cancer accounted for the largest market share followed by Chemotherapy.
By End User
Why purchase the report?
1.1 Research methodology
1.2 Scope of the Report
3.1 Market Drivers
3.2 Market Restraints
3.3 Porters Five Forces Analysis
3.3.1 Suppliers Power
3.3.2 Buyer Power
3.3.3 Industry Competition
3.3.4 Threat of new Entrant
3.3.5 Threat of Substitutes
7.1 Sunitinib Malate
8.3 Targeted Therapy
8.5 Other Medications
8.2 Oncology Centers
10.1 North America
10.1.1 United States
10.2.1 United Kingdom
10.2.5 Rest of Europe
10.3.5 Rest of Asia-Pacific
10.4 South America
10.4.3 Rest of South America
10.5 Rest of the World
11.1 Market Share Analysis
11.2 Company Benchmarking
11.3 Key Strategies Adopted by Major Companies
12.1 Novartis AG
12.2 Pfizer Inc.
12.4 Tarveda Therapeutics
12.5 Progenics Pharmaceuticals, Inc.
12.6 Hutchison Medipharma Limited
12.7 Dauntless Pharmaceuticals Inc.
12.8 Exelixis, Inc.
12.9 Advanced Accelerator Applications
12.10 Argos Therapeutics Inc
*Note: Additional company profiles will be included on request
Quick Fact: 7 of 10 customers Tailor their reports
10-year historic data for 1000+ markets
Ground-Zero understanding of the market with inputs from relevant industry association members
Tailored interviews with manufacturers, buyers, sellers, distributers and retailers for five-frame understanding of the market
Analysis of publicly available white label papers, news announcements, press releases, financial reports and reliable paid consulting data
7-step data formulation for market analysis and forecasts, under thorough scrutiny of industry-specific consultants with over 20+ years of expertise